MOTS-c

Safety Risk (1.2/5.0). Cleanest safety profile of any gray-market research peptide. MOTS-c is endogenous, so supraphysiological exposure from community doses remains within a range the body already clears through normal metabolic pathways. Zero organ toxicity across every published preclinical study (Lee 2015, Kim 2018, Ming 2016, Lu 2019, Zhai 2017). Zero deaths, zero serious adverse events, zero FDA FAERS reports. The CohBar CB4211 Phase 1a data showed tolerability in human subjects. Per v0.5 catastrophic-floor rules, no intrinsic life-threatening or permanently disabling adverse event has been documented. The real safety concern is extrinsic (supply-chain quality from research-peptide vendors), which per v0.5 compound-vs-supply-chain rules belongs in Verdict rather than the Safety Risk dimension score.

Side Effect Profile (1.3/5.0). Injection-site reactions (redness, mild transient swelling) are the most common reported effect in gray-market community tracking and cluster in the first week of dosing. Some users report fatigue days 1-3 of a new cycle, attributed to AMPK activation transiently shifting energy substrate preference before metabolic adaptation stabilizes. No rash, no GI upset, no headaches above placebo background, no mood disturbance, no sleep disruption. The absence of endocrine effects is notable versus peptides like CJC-1295 or tesamorelin where IGF-1 axis modulation produces characteristic signal. Community tracking across several hundred users finds fewer than 5% reporting any effect beyond injection site. Overall one of the most benign SE profiles in the peptide category.

Financial Cost (3.0/5.0). Gray-market pricing runs approximately $100-200/month for the standard 5 mg SC 3x/week protocol, depending on vendor quality tier and purchase volume. Reconstitution supplies (bacteriostatic water, insulin syringes, alcohol swabs) add roughly $10-20/month. No insurance coverage possible (not an approved indication anywhere in the world). No compounding-pharmacy channel exists because MOTS-c is not an approved API and cannot be legally compounded. Per v0.5 accessible-channels cost rules, the $100-200 range is the full accessible-channel reality because no legitimate regulated channel exists, so there is no retail premium to exclude. Score reflects the mid-range monthly cost against the supplement and peptide reference class.

Time/Effort Burden (3.0/5.0). Subcutaneous injections three times per week with reconstitution, refrigerated storage, abdominal rotation, and sharps disposal is meaningful friction compared to oral supplements at effectively zero effort. Vial reconstitution adds a few minutes per new vial; actual injection takes 30-60 seconds. The ongoing logistics overhead (cold-chain storage, supply tracking, vendor sourcing, cycling schedule, travel planning around dosing) is the real time cost rather than the injections themselves. Users already running other SC peptides (BPC-157, SS-31, tesamorelin) add MOTS-c with marginal additional effort; users new to injections face a real ramp-up period learning aseptic reconstitution technique. Score reflects moderate multi-week protocol burden, not the 30-second daily burden of an oral capsule.

Opportunity Cost (2.5/5.0). The cleanest opportunity-cost question for any exercise-mimetic peptide: could you just exercise instead? MOTS-c is literally described as an exercise mimetic because exogenous dosing reproduces AMPK activation that endogenous exercise already produces. For someone capable of regular exercise, the opportunity cost is real because money and injection effort could have gone to training gear, coaching, or time. For the indicated population (metabolically unhealthy, sedentary, aging, or unable to exercise due to physical limitation), per v0.5 audience-vs-indication rules the opportunity cost is minimal because the alternative is the status quo decline. Score reflects the average across both audiences with the healthy-biohacker filter pushed into the Verdict section.

Dependency/Withdrawal (1.0/5.0). No dependency signal in any published work, any community report, or any mechanistic prediction. Endogenous production continues independently of exogenous dosing (no feedback suppression mechanism is known for mitochondrial-derived peptides the way it exists for hormones or IGF-axis peptides). Stopping produces no rebound, no craving, no withdrawal symptoms. Per v0.5 dependency-vs-addiction framework, this is the substrate-class floor: the 1.0 score reflects absence of any known adaptation requiring continued dosing, no pharmacological tolerance, and no evidence of HPA-axis involvement. Community users who cycle 4 weeks on / 4 off report no withdrawal-phase symptoms beyond the absence of the felt energy signal itself.

Reversibility (1.0/5.0). Fully reversible. Stopping returns endogenous AMPK signaling to whatever age and exercise status baseline produces. No adaptation must be unwound. No persistent biomarker changes documented in community self-tracking after washout. No receptor downregulation or permanent epigenetic remodeling has been documented. The reversibility score sits at the 1.0 floor because the unknown-half-life caveat does not change the reversibility question: whatever the clearance half-life is, MOTS-c eventually clears without leaving persistent alterations. For a compound where the mechanism is substrate-level AMPK nudging rather than receptor remodeling, full reversibility is the mechanistic default.